241 related articles for article (PubMed ID: 29101238)
1. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
[TBL] [Abstract][Full Text] [Related]
3. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
[TBL] [Abstract][Full Text] [Related]
4. Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Bornhauser BC; Bonapace L; Lindholm D; Martinez R; Cario G; Schrappe M; Niggli FK; Schäfer BW; Bourquin JP
Blood; 2007 Sep; 110(6):2084-91. PubMed ID: 17537996
[TBL] [Abstract][Full Text] [Related]
5. MiR-124 contributes to glucocorticoid resistance in acute lymphoblastic leukemia by promoting proliferation, inhibiting apoptosis and targeting the glucocorticoid receptor.
Liang YN; Tang YL; Ke ZY; Chen YQ; Luo XQ; Zhang H; Huang LB
J Steroid Biochem Mol Biol; 2017 Sep; 172():62-68. PubMed ID: 28578002
[TBL] [Abstract][Full Text] [Related]
6. Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.
Evangelisti C; Cappellini A; Oliveira M; Fragoso R; Barata JT; Bertaina A; Locatelli F; Simioni C; Neri LM; Chiarini F; Lonetti A; Buontempo F; Orsini E; Pession A; Manzoli L; Martelli AM; Evangelisti C
J Cell Physiol; 2018 Mar; 233(3):1796-1811. PubMed ID: 28777460
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
8. [P38 mitogen-activated protein kinase mediates glucocorticoid receptor function induced by dexamethasone in acute lymphoblastic leukemia cells].
He L; Li D; Hou KZ; Liu YP
Zhonghua Er Ke Za Zhi; 2007 Sep; 45(9):687-91. PubMed ID: 18021564
[TBL] [Abstract][Full Text] [Related]
9. Anisomycin induces apoptosis of glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells via activation of mitogen-activated protein kinases p38 and JNK.
Liu Y; Ge J; Li Q; Gu L; Guo X; Ma ZG; Zhu YP
Neoplasma; 2013; 60(1):101-10. PubMed ID: 23067223
[TBL] [Abstract][Full Text] [Related]
10. Low-dose anisomycin sensitizes glucocorticoid-resistant T-acute lymphoblastic leukemia CEM-C1 cells to dexamethasone-induced apoptosis through activation of glucocorticoid receptor and p38-MAPK/JNK.
Liu Y; Ge J; Li Q; Guo X; Gu L; Ma ZG; Li XH; Zhu YP
Leuk Lymphoma; 2014 Sep; 55(9):2179-88. PubMed ID: 24597985
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
[TBL] [Abstract][Full Text] [Related]
12. Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.
Spenerova M; Dzubak P; Srovnal J; Radova L; Burianova R; Konecny P; Salkova S; Novak Z; Pospisilova D; Stary J; Blazek B; Hak J; Votava T; Timr P; Kaiserova E; Bubanska E; Mihal V; Hajduch M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014 Sep; 158(3):422-7. PubMed ID: 23128824
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin sensitizes glucocorticoid resistant acute lymphoblastic leukemia CEM-C1 cells to dexamethasone induced apoptosis through both mTOR suppression and up-regulation and activation of glucocorticoid receptor.
Guo X; Zhou CY; Li Q; Gao J; Zhu YP; Gu L; Ma ZG
Biomed Environ Sci; 2013 May; 26(5):371-81. PubMed ID: 23611130
[TBL] [Abstract][Full Text] [Related]
14. A novel method to establish glucocorticoid resistant acute lymphoblastic leukemia cell lines.
Gu L; Zhang G; Zhang Y
J Exp Clin Cancer Res; 2019 Jun; 38(1):269. PubMed ID: 31221196
[TBL] [Abstract][Full Text] [Related]
15. Akt2 mediates glucocorticoid resistance in lymphoid malignancies through FoxO3a/Bim axis and serves as a direct target for resistance reversal.
Xie M; Yang A; Ma J; Wu M; Xu H; Wu K; Jin Y; Xie Y
Cell Death Dis; 2019 Jan; 9(10):1013. PubMed ID: 30598523
[TBL] [Abstract][Full Text] [Related]
16. Expression differences in TEL-AML1 fusion gene in leukemia glucocorticoid-sensitive and -resistant cell lines.
Wang XW; Xu YH
Genet Mol Res; 2015 Jul; 14(3):7883-93. PubMed ID: 26214469
[TBL] [Abstract][Full Text] [Related]
17. PON2 blockade overcomes dexamethasone resistance in acute lymphoblastic leukemia.
Hui PY; Chen YH; Qin J; Jiang XH
Hematology; 2022 Dec; 27(1):32-42. PubMed ID: 34957927
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia.
Sarno J; Domizi P; Liu Y; Merchant M; Pedersen CB; Jedoui D; Jager A; Nolan GP; Gaipa G; Bendall SC; Bava FA; Davis KL
Nat Commun; 2023 May; 14(1):2935. PubMed ID: 37217509
[TBL] [Abstract][Full Text] [Related]
19. TCF7L2 activated HOXA-AS2 decreased the glucocorticoid sensitivity in acute lymphoblastic leukemia through regulating HOXA3/EGFR/Ras/Raf/MEK/ERK pathway.
Zhao Q; Zhao S; Li J; Zhang H; Qian C; Wang H; Liu J; Zhao Y
Biomed Pharmacother; 2019 Jan; 109():1640-1649. PubMed ID: 30551418
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte-Specific Chromatin Accessibility Pre-determines Glucocorticoid Resistance in Acute Lymphoblastic Leukemia.
Jing D; Huang Y; Liu X; Sia KCS; Zhang JC; Tai X; Wang M; Toscan CE; McCalmont H; Evans K; Mayoh C; Poulos RC; Span M; Mi J; Zhang C; Wong JWH; Beck D; Pimanda JE; Lock RB
Cancer Cell; 2018 Dec; 34(6):906-921.e8. PubMed ID: 30537513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
